National Surety Corp. v. Immunex Corp.

256 P.3d 439, 162 Wash. App. 762
CourtCourt of Appeals of Washington
DecidedJuly 25, 2011
Docket64712-1-I
StatusPublished
Cited by19 cases

This text of 256 P.3d 439 (National Surety Corp. v. Immunex Corp.) is published on Counsel Stack Legal Research, covering Court of Appeals of Washington primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
National Surety Corp. v. Immunex Corp., 256 P.3d 439, 162 Wash. App. 762 (Wash. Ct. App. 2011).

Opinion

Appelwick, J.

¶1 Immunex challenges the trial court ruling that National Surety does not have a duty to defend in several lawsuits challenging Immunex’s use of an inflated average wholesale price. National Surety cross appeals the trial court’s order that it compensate Immunex for defense costs until the time of the court’s ruling on the duty to defend unless it can show prejudice at trial. We affirm.

*767 FACTS

¶2 Immunex 1 Corporation and many other drug manufacturers were sued in at least 23 complaints (AWP litigation) alleging several claims relating to Immunex artificially inflating its average wholesale price (AWP). The claims included RICO (Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. §§ 1961-1968) claims, state unfair trade and protection statutes violations, civil conspiracy, fraud, and breach of contract.

¶3 To summarize the underlying litigation, physicians and other providers of drugs are reimbursed by Medicare and other third party payors based on the AWP of the drug. Manufacturers periodically report the AWP of drugs to publishers, who then list that price. Immunex and other drug manufacturers allegedly engaged in a scheme to fraudulently manipulate the AWP of their drugs. As part of this scheme, the claims allege that Immunex reported inflated AWPs, which materially misrepresented the actual prices paid to Immunex for prescription drugs by drug providers such as hospitals, pharmacies, and physicians. As a result, drug providers were reimbursed significantly more money than they paid for Immunex manufactured drugs. Also, the claims allege Immunex advertised the difference or “spread” in prices as a reason why those in the distribution chain should sell its drugs, thus increasing its share of the generic drug market. The plaintiffs in the AWP cases include consumers, third party payors, government entities, and consumer rights groups.

¶4 National Surety Corporation insured Immunex under an umbrella and excess liability insurance policy. The policy periods at issue are from September 1,1998 to September 1, 2002. On August 21, 2001, Immunex informed National Surety that potential claims had arisen against Immunex, *768 specifically a qui tam investigation 2 by the United States Department of Health and Human Services, as well as government investigations initiated by several states. Immunex also notified National Surety that the federal investigation related to a 1995 lawsuit. But, Immunex stated that it could not release information about the investigations because the government required a signed confidentiality agreement. National Surety acknowledged receipt of that notice on October 17, 2001. National Surety asked Immunex to send copies of the suit papers, when available, for it to determine coverage. On February 14, 2003, Immunex sent a status report, updating National Surety on the status of the investigations but not notifying National Surety of the AWP lawsuits or forwarding documentation related to those lawsuits. The first AWP litigation complaint was filed on November 27, 2001.

¶5 On October 3,2006, Immunex tendered defense of the AWP suits to National Surety and sought payment for the defense expenditures it had incurred. On October 30,2006, National Surety responded, disclaiming the duty to defend based on failure to provide suit papers and requesting the necessary documentation. On December 12,2006, Immunex sent copies of complaints, motions, and orders for some AWP cases.

¶6 The parties continued to discuss coverage. In March 2008, National Surety denied coverage but agreed under a reservation of rights to provide a defense with the right to obtain reimbursement of the amounts paid if it was determined by a court that there was no coverage or no duty to defend. Immunex alleges that National Surety has not paid any defense costs incurred in the AWP litigation.

¶7 Also in March 2008, National Surety filed this action, seeking a declaratory judgment that National Surety owed *769 no duties to Immunex under the policy. In June 2008, the trial court granted Immunex’s motion for a stay to prevent National Surety’s declaratory action from proceeding until the underlying litigation had been resolved. The stay was apparently granted before the parties conducted any discovery. On December 16, 2008, the stay was lifted solely to permit the parties to present motions on the issue of National Surety’s duty to defend.

¶8 Both parties presented motions for partial summary judgment on the issue of National Surety’s duty to defend Immunex in the AWP litigation. On April 15,2009, the trial court granted National Surety’s motion for summary judgment, determining that National Surety had no duty to defend.

¶9 After stipulating to again lift the stay, in July 2009, National Surety filed a motion for summary judgment regarding indemnity, 3 an alternative motion for summary judgment regarding late notice, and a motion for summary judgment regarding the payment of defense costs. Immunex also filed a motion for partial summary judgment regarding the payment of defense fees and costs. The trial court denied National Surety’s motion regarding payment of defense fees and costs and granted Immunex’s motion regarding same, finding that unless National Surety could prove prejudice from late notice at trial, it could be obligated to pay defense costs until the date the court confirmed the claims were not covered. The trial court denied National Surety’s motion to reconsider. The trial court then entered partial final judgment pursuant to CR 54(b) in order to permit this appeal to proceed.

¶10 Immunex appeals. National Surety cross appeals.

*770 DISCUSSION

I. Duty To Defend

¶11 Immunex alleges that the trial court erred when it granted summary judgment to National Surety on the basis that National Surety had no duty to defend Immunex in the AWP litigation. Immunex contends that National Surety owed a duty to defend Immunex against the AWP litigation under the “discrimination” provision of the policy.

¶12 A motion for summary judgment presents a question of law reviewed de novo. Osborn v. Mason County, 157 Wn.2d 18, 22, 134 P.3d 197 (2006). A trial court grants summary judgment if there is no genuine issue as to any material fact and the moving party is entitled to a judgment as a matter of law. CR 56(c).

¶13 Pursuant to the “personal injury” coverage within the policy at issue as modified by the endorsement, 4 National Surety was required to provide coverage for “Personal and Advertising injury that is caused by an offense arising out of [Immunex’s] business but only if the offense was committed during our Policy Period.” 5

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Crawford v. FCA US LLC
E.D. Michigan, 2021
National Surety Corporation v. Immunex Corporation
Court of Appeals of Washington, 2018
Ceco Concrete Construction, Llc. v. Suzanne Manchester
Court of Appeals of Washington, 2015
Ericka M. Rickman v. Premera Blue Cross
Court of Appeals of Washington, 2014
Karm Enterprises, Inc. v. Blue Ace, Llc
Court of Appeals of Washington, 2013
Gordon Woodley v. Usaa Casualty Ins. Company
Court of Appeals of Washington, 2013
National Surety Corp. v. Immunex Corp.
297 P.3d 688 (Washington Supreme Court, 2013)
Nat'l Sur. Corp. v. Immunex Corp.
Washington Supreme Court, 2013
Midmountain Contractors Inc. v. American Safety Indemnity Co.
893 F. Supp. 2d 1096 (W.D. Washington, 2012)
State v. Smith
256 P.3d 449 (Court of Appeals of Washington, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
256 P.3d 439, 162 Wash. App. 762, Counsel Stack Legal Research, https://law.counselstack.com/opinion/national-surety-corp-v-immunex-corp-washctapp-2011.